複方外用製劑市場－全球產業規模、佔有率、趨勢、機會及預測（依藥物類型、治療領域、最終用戶、地區及競爭格局分類，2021-2031年）

全球外用藥品市場預計將從 2025 年的 57.8 億美元成長到 2031 年的 76.9 億美元，複合年成長率為 4.87%。

這些複方藥物（包括乳膏、軟膏、洗劑和凝膠）由藥劑師根據患者的個別需求量身定做，滿足了標準批量生產藥物無法滿足的要求。推動這一市場成長的關鍵因素包括：需要精確劑量或對非處方藥中常見的防腐劑過敏的患者對個人化藥物的需求不斷成長；慢性皮膚病的日益普遍以及全球人口老齡化。

然而，由於複雜的法規環境和嚴格的報銷限制，這一領域面臨許多挑戰。第三方支付者通常拒絕為這些客製化複方藥物提供保險，從而限制了患者的負擔能力和用藥途徑。根據美國國家社區藥劑師協會 (NCPA) 2024 年報告的數據，47% 的獨立社區藥局提供複方藥物配製服務。儘管由於保險政策的不統一，醫療服務提供者和患者都面臨著經濟上的挑戰，但這一數字表明，儘管如此，藥房行業仍然為這些特殊治療做出了重大貢獻。

市場促進因素

推動市場擴張的關鍵因素是消費者對處方抗衰老齡化和美容療程的需求不斷成長，這主要源於患者越來越傾向於選擇脫髮症和皮膚問題的個人化治療方法。與標準非處方產品不同，外用處方藥可以根據個人膚質和耐受性進行客製化，其基質中含有多種活性成分，例如各種胜肽、米諾地爾和維A酸。這種個人化趨勢正在推動消費者遠端醫療平台的發展。例如，Hims & Hers Health, Inc. 在 2024 年第三季財報中宣布，截至 2024 年 11 月，其個人化解決方案的用戶已超過 100 萬，這表明消費者強烈希望透過個人化客製化來最佳化治療效果。

此外，全球供應鏈中斷和非處方藥短缺迫使醫療系統在FDA認證核可藥無法取得時，依賴複方外用藥物作為必要的替代方案。供應鏈的脆弱性導致頻繁的斷貨，使得依賴503A藥局和503B合約配藥機構對於維持醫療服務的連續性至關重要。根據美國衛生系統藥劑師協會（ASHP）截至2024年4月的藥品短缺統計數據，美國在當年第一季經歷了323起藥品短缺事件，創歷史新高。這些持續的藥品短缺正在推動該行業的財務業績成長，Fagron公司2024會計年度全年財務業績（於2025年2月公佈）顯示，受配藥服務和原料的持續需求驅動，其銷售額成長了14.3%。

市場挑戰

全球複方外用藥物市場面臨日益複雜的法規結構和第三方支付方嚴格的報銷通訊協定帶來的許多限制。保險公司和藥品福利管理機構通常將客製化外用製劑歸類為「研究性」或「非必需」藥物，導致其經常被拒付。這對因皮膚過敏等問題而臨床上需要這些特殊製劑的患者造成了巨大的障礙。強制患者自費支付全部費用會降低患者對這些個人化療法的依從性，進而減少業務量並限制該行業的收入潛力。

這種嚴峻的經濟環境也威脅著提供這些藥物的藥局的永續性。根據美國國家社區藥劑師協會 (NCPA) 2024 年的一項調查，超過半數的受訪藥房業主表示，他們所配的處方中至少有十分之三的處方箋，其來自保險計劃和藥品福利管理機構 (PBM) 的報銷金額低於採購成本。當報銷金額無法覆蓋成本時，藥房便失去了維持必要的專業人員和庫存的經濟獎勵，而這些人員和庫存對於配發外用藥物至關重要。這種壓力導致醫療服務網路萎縮，限制了患者獲得必要治療的機會，並阻礙了市場成長。

市場趨勢

為了確保複雜外用製劑的準確性和一致性，機器人和自動化混合技術的整合正迅速成為藥房行業的標準做法。隨著對活性成分濃度和一致性的監管日益嚴格，這些自動化系統可以最大限度地減少人為錯誤，並提高定製藥物的安全性，尤其對於處理大量皮膚科藥物的大型醫療機構而言更是如此。根據《藥局採購與產品》雜誌2024年8月發布的《自動化配藥設備》報告，48%擁有400張或以上床位的醫療機構已採用自動化配藥技術，這標誌著為確保藥物供應的一致性，醫療機構正朝著現代化基礎設施邁出重要一步。

同時，開發旨在增強經皮吸收的先進專有基質已成為對穩定性和吸收性要求極高的藥物製劑的關鍵趨勢。製造商正積極拓展其特種基質產品線，這些基質能夠有效遞送多種活性成分，例如荷爾蒙和鎮痛藥物，使其穿過皮膚屏障而不影響療效。這種對產品創新的重視正為主要產業參與者帶來強勁的財務表現。例如，Fagron公司報告稱，其2024會計年度上半年（截至2024年8月）的銷售額成長了15.5%，這主要得益於其「品牌與必需品」業務板塊的擴張，該板塊涵蓋了這些特種製劑基質。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球複雜外用製劑市場展望

• 市場規模及預測
  • 按金額
• 市佔率及預測
  • 依藥物類型（外用荷爾蒙製劑、外用止痛藥、外用抗真菌/抗菌製劑、外用皮膚科製劑、創傷治療劑、其他）
  • 依治療領域（疼痛管理、皮膚病及皮膚科、荷爾蒙療法、感染疾病、其他）
  • 按最終用戶（醫院/診所、藥房/零售藥局、居家醫療機構、其他）
  • 按地區
  • 按公司（2025 年）
• 市場地圖

6. 北美組合外用製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 北美洲：國家分析
  • 美國
  • 加拿大
  • 墨西哥

7. 歐洲組合外用製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 歐洲：國家分析
  • 德國
  • 法國
  • 英國
  • 義大利
  • 西班牙

8. 亞太地區複方外用製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 亞太地區：國家分析
  • 中國
  • 印度
  • 日本
  • 韓國
  • 澳洲

9. 中東和非洲組合外用製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 中東和非洲：國家分析
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 南非

第10章 南美洲複方外用製劑市場展望

• 市場規模及預測
• 市佔率及預測
• 南美洲：國家分析
  • 巴西
  • 哥倫比亞
  • 阿根廷

第11章 市場動態

• 促進要素
• 任務

第12章 市場趨勢與發展

• 併購
• 產品發布
• 最新進展

第13章 全球複方外用製劑市場：SWOT分析

第14章：波特五力分析

• 產業競爭
• 新進入者的可能性
• 供應商電力
• 顧客權力
• 替代品的威脅

第15章 競爭格局

• Fresenius Kabi AG
• B. Braun SE
• Hisamitsu Pharmaceutical Co., Inc.
• Glenmark Pharmaceuticals Ltd.
• Optum Inc.
• Nephron Pharmaceuticals Corporation
• Sun Pharmaceutical Industries Ltd.
• Central Admixture Pharmacy Services, Inc.
• CareFirst Specialty Pharmacy
• Medisca Inc.

第16章 策略建議

第17章：關於研究公司及免責聲明

The Global Compounded Topical Drug Market is projected to expand from USD 5.78 Billion in 2025 to USD 7.69 Billion by 2031, registering a CAGR of 4.87%. These compounded medications-encompassing creams, ointments, lotions, and gels-are bespoke pharmaceutical preparations created by pharmacists to address unique patient requirements that standard mass-produced drugs cannot fulfill. Key factors fueling this market growth include the escalating demand for personalized medicine, specifically for individuals needing precise dosage strengths or those with allergies to preservatives common in commercial products, alongside the rising prevalence of chronic skin disorders and an aging global population.

However, the sector encounters substantial obstacles due to a complicated regulatory environment and strict reimbursement limitations, as third-party payers often refuse coverage for these customized formulations, thereby restricting affordability and patient access. Data from the National Community Pharmacists Association's 2024 NCPA Digest reveals that 47 percent of independent community pharmacies provide compounding services. This figure highlights the significant commitment of the pharmacy industry to these specialized therapies, even as providers and patients alike struggle with the financial difficulties resulting from inconsistent insurance coverage policies.

Market Driver

A major catalyst driving market expansion is the growing consumer demand for anti-aging and aesthetic compounded treatments, as patients increasingly pursue tailored regimens for hair loss and dermatological issues. Unlike standard commercial options, compounded topicals enable the formulation of specific bases containing multiple active ingredients-such as various peptides, minoxidil, and tretinoin-customized to an individual's skin type and tolerance. This shift toward personalization has accelerated the growth of direct-to-consumer telehealth platforms; for example, Hims & Hers Health, Inc. reported in their Third Quarter 2024 Financial Results that subscribers utilizing personalized solutions surpassed 1 million in November 2024, illustrating a strong preference for efficacy optimized by customization.

Additionally, global supply chain disruptions and commercial drug shortages compel the healthcare system to rely on compounded topical drugs as essential alternatives when FDA-approved medications are unobtainable. Vulnerabilities in the supply chain have caused frequent stockouts, necessitating reliance on 503A pharmacies and 503B outsourcing facilities to maintain care continuity. According to the American Society of Health-System Pharmacists' Drug Shortages Statistics from April 2024, the U.S. reached a record high of 323 active drug shortages in the first quarter of that year. This persistent scarcity has bolstered the industry's financial performance, as evidenced by Fagron's Full Year Results 2024 (February 2025), which reported a 14.3% increase in topline revenue driven by the enduring demand for compounding services and ingredients.

Market Challenge

The Global Compounded Topical Drug Market faces severe restrictions due to an increasingly intricate regulatory framework and rigorous reimbursement protocols imposed by third-party payers. Insurance companies and pharmacy benefit managers often categorize customized topical preparations as investigational or non-essential, resulting in frequent coverage denials that create substantial barriers for patients who clinically require these specialized formulations due to issues like dermatological allergies. As patients are forced to bear the full financial cost, adherence to these tailored therapies diminishes, which in turn reduces transaction volumes and limits the sector's revenue potential.

This difficult economic climate also jeopardizes the operational sustainability of pharmacies providing these medications. According to the National Community Pharmacists Association in 2024, over half of surveyed pharmacy owners indicated that reimbursements from insurance plans and pharmacy benefit managers fell below the acquisition cost for at least three out of every ten prescriptions filled. When reimbursement rates fail to cover the cost of goods, pharmacies are financially disincentivized from maintaining the specialized staffing and inventory necessary for compounding topicals, a pressure that hinders market growth by shrinking the provider network and restricting patient access to essential treatments.

Market Trends

The integration of robotics and automated mixing technologies is rapidly becoming a standard practice in compounding to guarantee the precision and homogeneity of complex topical formulations. As pharmacies encounter tighter regulatory requirements regarding potency and uniformity, adopting these automated systems helps minimize human error and improves the safety profile of customized drugs, particularly in large healthcare institutions managing high volumes of dermatological preparations. According to the August 2024 "Automated Compounding Devices" report by Pharmacy Purchasing & Products, 48% of facilities with 400 or more beds have implemented automated compounding technology, signaling a significant shift toward modern infrastructure to ensure consistent drug delivery.

Concurrently, the development of advanced proprietary bases designed for enhanced transdermal delivery has emerged as a crucial trend, driven by the necessity for superior stability and absorption in compounded agents. Manufacturers are actively broadening their portfolios of specialized bases capable of effectively delivering multiple active ingredients, such as hormones or pain modulators, across the skin barrier without reducing efficacy. This emphasis on product innovation has led to strong financial outcomes for major industry players; for instance, Fagron reported a 15.5% revenue increase in its First Half Results 2024 (August 2024), a performance largely underpinned by the expansion of its Brands and Essentials segment, which includes these specialized compounding vehicles.

Key Market Players

• Fresenius Kabi AG
• B. Braun SE
• Hisamitsu Pharmaceutical Co., Inc.
• Glenmark Pharmaceuticals Ltd.
• Optum Inc.
• Nephron Pharmaceuticals Corporation
• Sun Pharmaceutical Industries Ltd.
• Central Admixture Pharmacy Services, Inc.
• CareFirst Specialty Pharmacy
• Medisca Inc.

Report Scope

In this report, the Global Compounded Topical Drug Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Compounded Topical Drug Market, By Drug Type

• Hormonal Topicals
• Pain Relief Topicals
• Antifungal and Antibacterial Topicals
• Dermatological Topicals
• Wound Healing
• Others

Compounded Topical Drug Market, By Therapeutic Area

• Pain Management
• Skin Disorders and Dermatology
• Hormonal Therapy
• Infections
• Others

Compounded Topical Drug Market, By End User

• Hospitals and Clinics
• Pharmacies and Retail Drug Stores
• Homecare Settings
• Others

Compounded Topical Drug Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Compounded Topical Drug Market.

Available Customizations:

Global Compounded Topical Drug Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Compounded Topical Drug Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Type (Hormonal Topicals, Pain Relief Topicals, Antifungal and Antibacterial Topicals, Dermatological Topicals, Wound Healing, Others)
  • 5.2.2. By Therapeutic Area (Pain Management, Skin Disorders and Dermatology, Hormonal Therapy, Infections, Others)
  • 5.2.3. By End User (Hospitals and Clinics, Pharmacies and Retail Drug Stores, Homecare Settings, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Compounded Topical Drug Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Type
  • 6.2.2. By Therapeutic Area
  • 6.2.3. By End User
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Compounded Topical Drug Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Type
      • 6.3.1.2.2. By Therapeutic Area
      • 6.3.1.2.3. By End User
  • 6.3.2. Canada Compounded Topical Drug Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Type
      • 6.3.2.2.2. By Therapeutic Area
      • 6.3.2.2.3. By End User
  • 6.3.3. Mexico Compounded Topical Drug Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Type
      • 6.3.3.2.2. By Therapeutic Area
      • 6.3.3.2.3. By End User

7. Europe Compounded Topical Drug Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Type
  • 7.2.2. By Therapeutic Area
  • 7.2.3. By End User
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Compounded Topical Drug Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Type
      • 7.3.1.2.2. By Therapeutic Area
      • 7.3.1.2.3. By End User
  • 7.3.2. France Compounded Topical Drug Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Type
      • 7.3.2.2.2. By Therapeutic Area
      • 7.3.2.2.3. By End User
  • 7.3.3. United Kingdom Compounded Topical Drug Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Type
      • 7.3.3.2.2. By Therapeutic Area
      • 7.3.3.2.3. By End User
  • 7.3.4. Italy Compounded Topical Drug Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Drug Type
      • 7.3.4.2.2. By Therapeutic Area
      • 7.3.4.2.3. By End User
  • 7.3.5. Spain Compounded Topical Drug Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Drug Type
      • 7.3.5.2.2. By Therapeutic Area
      • 7.3.5.2.3. By End User

8. Asia Pacific Compounded Topical Drug Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Type
  • 8.2.2. By Therapeutic Area
  • 8.2.3. By End User
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Compounded Topical Drug Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Type
      • 8.3.1.2.2. By Therapeutic Area
      • 8.3.1.2.3. By End User
  • 8.3.2. India Compounded Topical Drug Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Type
      • 8.3.2.2.2. By Therapeutic Area
      • 8.3.2.2.3. By End User
  • 8.3.3. Japan Compounded Topical Drug Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Type
      • 8.3.3.2.2. By Therapeutic Area
      • 8.3.3.2.3. By End User
  • 8.3.4. South Korea Compounded Topical Drug Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Drug Type
      • 8.3.4.2.2. By Therapeutic Area
      • 8.3.4.2.3. By End User
  • 8.3.5. Australia Compounded Topical Drug Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Drug Type
      • 8.3.5.2.2. By Therapeutic Area
      • 8.3.5.2.3. By End User

9. Middle East & Africa Compounded Topical Drug Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Type
  • 9.2.2. By Therapeutic Area
  • 9.2.3. By End User
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Compounded Topical Drug Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Type
      • 9.3.1.2.2. By Therapeutic Area
      • 9.3.1.2.3. By End User
  • 9.3.2. UAE Compounded Topical Drug Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Type
      • 9.3.2.2.2. By Therapeutic Area
      • 9.3.2.2.3. By End User
  • 9.3.3. South Africa Compounded Topical Drug Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Type
      • 9.3.3.2.2. By Therapeutic Area
      • 9.3.3.2.3. By End User

10. South America Compounded Topical Drug Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Drug Type
  • 10.2.2. By Therapeutic Area
  • 10.2.3. By End User
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Compounded Topical Drug Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Drug Type
      • 10.3.1.2.2. By Therapeutic Area
      • 10.3.1.2.3. By End User
  • 10.3.2. Colombia Compounded Topical Drug Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Drug Type
      • 10.3.2.2.2. By Therapeutic Area
      • 10.3.2.2.3. By End User
  • 10.3.3. Argentina Compounded Topical Drug Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Drug Type
      • 10.3.3.2.2. By Therapeutic Area
      • 10.3.3.2.3. By End User

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Compounded Topical Drug Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. Fresenius Kabi AG
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. B. Braun SE
• 15.3. Hisamitsu Pharmaceutical Co., Inc.
• 15.4. Glenmark Pharmaceuticals Ltd.
• 15.5. Optum Inc.
• 15.6. Nephron Pharmaceuticals Corporation
• 15.7. Sun Pharmaceutical Industries Ltd.
• 15.8. Central Admixture Pharmacy Services, Inc.
• 15.9. CareFirst Specialty Pharmacy
• 15.10. Medisca Inc.

16. Strategic Recommendations

17. About Us & Disclaimer